Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,147.75
-22.30 (-1.91%)
Feb 18, 2025, 9:15 AM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 79.79B INR in the quarter ending December 31, 2024, with 8.53% growth. This brings the company's revenue in the last twelve months to 309.22B, up 10.85% year-over-year. In the fiscal year ending March 31, 2024, Aurobindo Pharma had annual revenue of 290.02B with 16.68% growth.
Revenue (ttm)
309.22B
Revenue Growth
+10.85%
P/S Ratio
2.20
Revenue / Employee
11.89M
Employees
26,015
Market Cap
675.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
Mar 31, 2020 | 230.99B | 35.35B | 18.07% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Zydus Lifesciences | 222.47B |
Apollo Hospitals Enterprise | 211.46B |
Alkem Laboratories | 127.57B |
Fortis Healthcare | 75.61B |
Aurobindo Pharma News
- 6 days ago - Pharma stocks rally: Aurobindo Pharma up 4.05%, Lupin jumps 3.81%, Biocon gains 2.80% at market open - Business Upturn
- 12 days ago - Aurobindo Pharma’s API Unit 2 in Telangana receives VAI classification from US FDA, EIR issued - Business Upturn
- 22 days ago - Aurobindo Pharma subsidiary’s facility receives EIR from US FDA with VAI classification - Business Upturn
- 27 days ago - Brokerage Report: CLSA expects India pharma market to grow at 8-9% in 2025, Dr. Reddy’s downgraded to ‘Underperform’, Aurobindo Pharma upgraded to ‘Outperform’ - Business Upturn
- 4 weeks ago - Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84% - Business Upturn
- 4 weeks ago - Pharma sector stocks: Biocon (+3.10%), Aurobindo Pharma (+0.48%), Divis Labs (+0.39%) rise; Mankind Pharma (-1.43%) leads losers - Business Upturn
- 6 weeks ago - Pharma stocks: Dr. Reddy’s up 1.70%, Biocon down 2.17%, Lupin falls 2.18% - Business Upturn
- 6 weeks ago - Pharma sector stocks performance: Ipca Labs gains 1.23%, Biocon up 0.84%, Sun Pharma and Torrent Pharma slip over 1% - Business Upturn